Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Inpharmatics Establishes New Business Unit Rosetta Biosoftware

NEW YORK, Sept. 20 – Merck's wholly owned subsidiary Rosetta Inpharmatics said Thursday it had established a new business unit, Rosetta Biosoftware, to develop and sell new bioinformatics software for life science research.

The new business unit, which will be based in Kirkland, Wash., will continue to develop new versions of Rosetta’s flagship product, the Rosetta Resolver Gene Expression Data Analysis System.

Agilent Technologies will remain the exclusive distributor of Rosetta software.

Douglas Bassett, formerly senior director of biosoftware products and services at Rosetta Inpharmatics, will be the general manager of the new business unit, which will initially have 50 employees.

"Rosetta Biosoftware's mission is to create best-of-breed bioinformatics software solutions for life science research," Bassett said in a statement. "In the tradition of the Rosetta Resolver system, we will develop pioneering solutions that enable research in gene expression, proteomics, and other areas of discovery."

Rosetta Inpharmatics will continue to develop genomic technologies for drug discovery. The company focuses on how medical compounds affect biology.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.